

Fabrice Le Boeuf

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8955406/fabrice-le-boeuf-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|-----------------|-----------------|
| 38 papers | 3,008 citations | 23 h-index | 38 g-index |
| 38 ext. papers | 3,382 ext. citations | 11.6 avg, IF | 4.73 L-index |

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 38 | Endothelial cell migration during angiogenesis. <i>Circulation Research</i> , 2007 , 100, 782-94 | 15.7 | 978 |
| 37 | Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. <i>Nature</i> , 2011 , 477, 99-102 | 50.4 | 392 |
| 36 | The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. <i>Molecular Therapy</i> , 2012 , 20, 749-58 | 11.7 | 177 |
| 35 | Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. <i>PLoS Medicine</i> , 2007 , 4, e353 | 11.6 | 154 |
| 34 | Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. <i>Molecular Biology of the Cell</i> , 2007 , 18, 4659-68 | 3.5 | 123 |
| 33 | Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. <i>Journal of Biological Chemistry</i> , 2004 , 279, 39175-85 | 5.4 | 114 |
| 32 | Synergistic interaction between oncolytic viruses augments tumor killing. <i>Molecular Therapy</i> , 2010 , 18, 888-95 | 11.7 | 97 |
| 31 | Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015 , 21, 530-6 | 50.5 | 93 |
| 30 | Smac mimetics and innate immune stimuli synergize to promote tumor death. <i>Nature Biotechnology</i> , 2014 , 32, 182-90 | 44.5 | 92 |
| 29 | A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. <i>Molecular Therapy</i> , 2010 , 18, 1123-9 | 11.7 | 67 |
| 28 | VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015 , 28, 210-24 | 24.3 | 62 |
| 27 | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. <i>Molecular Therapy</i> , 2012 , 20, 1791-9 | 11.7 | 56 |
| 26 | Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. <i>Molecular Therapy</i> , 2018 , 26, 56-69 | 11.7 | 55 |
| 25 | Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. <i>PLoS ONE</i> , 2010 , 5, e14462 | 3.7 | 54 |
| 24 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncol Immunology</i> , 2018 , 7, e1503032 | 7.2 | 50 |
| 23 | Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. <i>Journal of Virology</i> , 2010 , 84, 856-66 | 6.6 | 46 |
| 22 | Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , 2015 , 6, 6410 | 17.4 | 36 |

| | | | |
|----|--|------|----|
| 21 | Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. <i>Molecular Therapy</i> , 2014 , 22, 1188-1197 | 11.7 | 27 |
| 20 | Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. <i>Methods in Molecular Biology</i> , 2012 , 797, 127-40 | 1.4 | 27 |
| 19 | Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models. <i>Molecular Therapy - Oncolytics</i> , 2017 , 6, 80-89 | 6.4 | 26 |
| 18 | Potent oncolytic activity of racoonpox virus in the absence of natural pathogenicity. <i>Molecular Therapy</i> , 2010 , 18, 896-902 | 11.7 | 25 |
| 17 | Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , 2018 , 7, 117-128 | 11.7 | 24 |
| 16 | Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. <i>International Journal of Cancer</i> , 2017 , 141, 1257-1264 | 11.7 | 23 |
| 15 | Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 3832-43 | 12.9 | 23 |
| 14 | First-in-class small molecule potentiators of cancer virotherapy. <i>Scientific Reports</i> , 2016 , 6, 26786 | 4.9 | 21 |
| 13 | Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. <i>Onc Immunology</i> , 2018 , 7, e1407897 | 7.2 | 20 |
| 12 | Single-particle characterization of oncolytic vaccinia virus by flow virometry. <i>Vaccine</i> , 2016 , 34, 5082-5089 | 7.1 | 19 |
| 11 | Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. <i>Molecular Therapy - Oncolytics</i> , 2020 , 17, 232-240 | 6.4 | 18 |
| 10 | Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 221-227 | 8.9 | 17 |
| 9 | Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. <i>Journal of Virology</i> , 2013 , 87, 2363-6 | 6.6 | 15 |
| 8 | United virus: the oncolytic tag-team against cancer!. <i>Cytokine and Growth Factor Reviews</i> , 2010 , 21, 205-11 | 11.9 | 14 |
| 7 | Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. <i>International Journal of Cancer</i> , 2012 , 131, E204-15 | 7.5 | 13 |
| 6 | Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. <i>PLoS Pathogens</i> , 2018 , 14, e1007264 | 7.6 | 11 |
| 5 | Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. <i>International Journal of Cancer</i> , 2013 , 132, 726-31 | 7.5 | 10 |
| 4 | Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. <i>Molecular Therapy - Oncolytics</i> , 2019 , 14, 246-252 | 6.4 | 9 |

| | | | |
|---|---|-----|---|
| 3 | Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016 , 3, 16027 | 6.4 | 9 |
| 2 | High-throughput titration of luciferase-expressing recombinant viruses. <i>Journal of Visualized Experiments</i> , 2014 , 51890 | 1.6 | 6 |
| 1 | The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses. <i>Oncolytic Virotherapy</i> , 2017 , 7, 25-35 | 6 | 5 |